<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024305</url>
  </required_header>
  <id_info>
    <org_study_id>TWP-102-11</org_study_id>
    <nct_id>NCT05024305</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.</brief_title>
  <official_title>A Multi-center, Phase I, Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong TheraWisdom Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong TheraWisdom Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, phase I, open clinical study to evaluate the safety, tolerability,&#xD;
      pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of TWP-102 injection in&#xD;
      patients with advanced malignancies. This study consists of two parts, including a dose&#xD;
      escalation study and a dose expansion study. The criteria for dose escalation will be based&#xD;
      on the Bayesian optimal interval (BOIN) design with sequentially enrolled cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events/serious adverse event related with TWP-102 injection</measure>
    <time_frame>From enrollment until 90 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>From the first dose of study drug up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax) of TWP-102 injection.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of TWP-102 injection.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of TWP-102 injection.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of TWP-102 injection.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
    <description>Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies and neutralizing antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four dose levels of TWP-102 injection will be tested by BOIN study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the effective doses have been determined, two expansion cohorts will be opened to evaluate the efficacy and safety in one or two tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TWP-102 injection</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed advanced malignancies that failed, or not suitable for&#xD;
             standard treatments;&#xD;
&#xD;
          -  At least 1 measurable lesion.&#xD;
&#xD;
          -  ECOG score 0 or 1;&#xD;
&#xD;
          -  Life expectancy of â‰¥ 3 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any ingredient of TWP-102;&#xD;
&#xD;
          -  Receiving any anti-cancer drugs within 4 weeks;&#xD;
&#xD;
          -  History of serious systemic diseases;&#xD;
&#xD;
          -  History of serious autoimmune diseases;&#xD;
&#xD;
          -  Persistent toxicity of National Cancer Institute (NCI) Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) version 5.0 Grade &gt; 1 severity that is related to prior&#xD;
             anti-cancer therapy. (except alopecia)&#xD;
&#xD;
          -  Pregnancy or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shengbin Ren</last_name>
    <phone>8021-60167707</phone>
    <email>shengbin.ren@therawisdom.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
      <phone>0451-86298070</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

